about
Maintenance chemotherapy for ovarian cancerMaintenance bioimmunotherapy for epithelial ovarian cancerMaintenance chemotherapy for ovarian cancerCancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinomaAntigen-specific immunotherapy of cervical and ovarian cancerSulforaphane induces cell cycle arrest by protecting RB-E2F-1 complex in epithelial ovarian cancer cellsEpithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology.Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancerIntra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II studyThe glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration.Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancerThe Eag potassium channel as a new prognostic marker in ovarian cancer.Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer.An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cellsA phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan arrayPhase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer.Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.Microtubule inhibitor, SP-6-27 inhibits angiogenesis and induces apoptosis in ovarian cancer cells.Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatmentTherapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerThe significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome.Targeted Disruption of the JAK2/STAT3 Pathway in Combination with Systemic Administration of Paclitaxel Inhibits the Priming of Ovarian Cancer Stem Cells Leading to a Reduced Tumor Burden.Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cellsThe apoptotic mechanisms of MT-6, a mitotic arrest inducer, in human ovarian cancer cells.Development of a mouse model of menopausal ovarian cancer.Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma.In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.BMP-4 expression has prognostic significance in advanced serous ovarian carcinoma and is affected by cisplatin in OVCAR-3 cells.Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs.Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model.High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis.Open source machine-learning algorithms for the prediction of optimal cancer drug therapies.Expression and effects of modulation of the K2P potassium channels TREK-1 (KCNK2) and TREK-2 (KCNK10) in the normal human ovary and epithelial ovarian cancer.Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells.The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility.Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy
P2860
Q24201758-DBE5653F-F2F4-44DB-BEE1-1F38A3076A1FQ24234761-C34435E0-4E5F-476E-AF55-65FC0840A888Q24235427-D6E766B7-A6E9-46F9-9109-56802AD59027Q26998068-79D0D623-516A-4370-980F-36A47A83BA35Q27488697-8A9BB8FE-41F7-49E2-913F-9AE917879B15Q33728766-45ECF96E-9EAE-491F-BC24-6EC3323CB4C9Q33872622-4EDDB78D-B366-4E51-A3DE-7048A4581466Q34060699-2CEF321B-2B20-4654-ABEC-04AF2127FAD9Q34354529-687424A6-1131-4702-86A3-B36683FB5A00Q34354596-E2C2268A-0A6B-4701-B22C-8DAA043E68CCQ34397197-B615DFB6-EB64-41C2-956B-10378EDD5A60Q34468285-E81B89B3-CD30-4F79-B24B-4E8CB7671BC1Q34577121-179B8C27-A859-4F91-9675-4B0036DB9661Q34770077-97887FDB-D3FB-43C3-BB3F-A2C4D5FB9973Q34995009-4E429B04-28F7-4F91-9709-7B2C9153D637Q35109145-EC51B3FD-F665-4610-B03E-0D329F4405DEQ35653739-1E8FE580-203F-48E7-BFA3-0389D25BC0EEQ35869447-E86C81A5-C3F4-4709-95B8-441F6B932588Q36169039-4FC63E5A-B89A-444C-9F55-22A2CFCDC7D5Q36226627-CB7A37E7-388A-4C99-B094-A3B18A36EEC2Q36381403-669FAB12-12CA-49C9-A0DF-AFF34AE575AAQ37096241-22E10863-D2F8-4A65-9C34-FC601FA86DEAQ37213050-00EEB7D0-F29E-4240-9F24-630DB350BA5AQ37365673-308C5F0E-D1FF-4BD1-A42A-C154D35A7066Q37687176-BD77F06A-F6A2-49A3-9918-0A4A699B48DCQ37705457-CB5A34C5-C854-4E41-8878-D09840690CD0Q37706855-BC565782-366B-4D53-B69C-A8CEA365BECAQ37741008-85EC6A00-1F03-4955-B8FC-81F9B9BB4016Q38195046-0021E801-0D69-4CB1-AABA-89E31A7FF28FQ38602517-2E5B457C-213B-490D-ACBB-5D2C0E1E65B8Q39080600-51B8D004-1573-43DE-B350-3D76378948EEQ39524316-D1F02FD0-3604-4CC0-925E-E5E26C7BEA79Q39872610-C77188E7-53DE-40F7-95DE-5FCD294D1691Q40056618-7D70A335-B4AA-44F3-8F6B-67D869C22FCEQ40077912-AABA0B49-29C1-4DA0-A9F3-3B584D890C69Q42699335-FCD9844F-491D-411A-B206-297DDCAF6ADBQ44967488-25675D73-B6B9-4721-A219-71F7843BF8A5Q52571253-6C16A385-DA1F-41ED-BD9E-C12136724900Q55452303-93CAA687-C9F4-4FB6-B5AF-99069E9F7F37Q58608801-90FDC68F-5EB3-4CB9-B0B4-5D6E41B02F71
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Challenges for chemotherapy in ovarian cancer.
@ast
Challenges for chemotherapy in ovarian cancer.
@en
type
label
Challenges for chemotherapy in ovarian cancer.
@ast
Challenges for chemotherapy in ovarian cancer.
@en
prefLabel
Challenges for chemotherapy in ovarian cancer.
@ast
Challenges for chemotherapy in ovarian cancer.
@en
P356
P1433
P1476
Challenges for chemotherapy in ovarian cancer.
@en
P2093
P304
P356
10.1093/ANNONC/MDJ978
P478
17 Suppl 5
P577
2006-05-01T00:00:00Z